

**Fellow Publications/Presentations
January through December 2021**

Publications

1. Patel BJ, **Barot SV**, Xie Y, Cook JR, Carraway HE, Hsi ED. Impact of next generation sequencing results on clinical management in patients with hematological disorders. *Leuk Lymphoma*. 2021 Jul;62(7):1702-1710. doi: 10.1080/10428194.2021.1876860. Epub 2021 Feb 3. PMID: 33533694.
2. Granat LM, Singh AD, **Cortese M**, Velez V, Lichtin A. Severe thrombocytopenia in a patient with otherwise asymptomatic COVID-19. *Cleve Clin J Med*. 2021 Feb 1;88(2):86-92. doi: 10.3949/ccjm.88a.20154. PMID: 33526461.
3. **Dawsey SJ**, Campbell SC, Ornstein MC. Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. *Curr Oncol*. 2021 May 20;28(3):1921-1926. doi: 10.3390/currenocol28030178. PMID: 34065284; PMCID: PMC8161823.
4. Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, **Dawsey SJ**, et. al. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. *JAMA Netw Open*. 2021 Nov 1;4(11):e2134330. doi: 10.1001/jamanetworkopen.2021.34330. Erratum in: *JAMA Netw Open*. 2021 Dec 1;4(12):e2145075. PMID: 34767021; PMCID: PMC8590166.
5. **Dawsey SJ**, Ornstein MC. Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. *Curr Oncol*. 2021 Nov 30;28(6):5019-5024. doi: 10.3390/currenocol28060421. PMID: 34940060; PMCID: PMC8700734.
6. **DeSouza S**, Angelini D. Updated guidelines for immune thrombocytopenic purpura: Expanded management options. *Cleve Clin J Med*. 2021 Dec 2;88(12):664-668. doi: 10.3949/ccjm.88a.20201. PMID: 34857604.
7. Varghese AM, Singh I, Singh R, **Kunte S**, et. al. Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. *J Natl Cancer Inst*. 2021 Sep 4;113(9):1194-1202. doi: 10.1093/jnci/djab038. PMID: 33755158; PMCID: PMC8418394.
8. Catania C, **Muthusamy B**, Spitaleri G, Del Signore E, Pennell NA. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. *Clin Lung Cancer*. 2022 Mar;23(2):108-115. doi: 10.1016/j.clcc.2021.11.003. Epub 2021 Nov 11. PMID: 34952792.
9. Chakraborty P, Rose RA, **Nair K**, Downar E, Nanthakumar K. The rationale for repurposing funny current inhibition for management of ventricular arrhythmia. *Heart Rhythm*. 2021 Jan;18(1):130-137. doi: 10.1016/j.hrthm.2020.07.031. Epub 2020 Jul 29. PMID: 32738405.
10. Thompson MA, Henderson JP, Shah PK...COVID-19 and Cancer Consortium [including **Nizam A**]. Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021;7(8):1167-1175. PMID: 34137799

11. Grivas P, Khaki AR, Wise-Draper TM, et al [including **Nizam A**]. Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium. *Ann. Oncol.* 2021;32(6):787-800. PMID: 33746047
12. Leddon JL, Chirra M, Frankart AJ, Agrawal A, **Roof L**, et. al. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors. *Laryngoscope.* 2021 Jul;131(7):E2413-E2419. doi: 10.1002/lary.29451. Epub 2021 Feb 20. PMID: 33609046.
13. Mehta N, Abushahin A, **Sadaps M**, et. al. Recurrence with malignancy after endoscopic resection of large colon polyps with high-grade dysplasia: incidence and risk factors. *Surg Endosc.* 2021 Jun;35(6):2500-2508. doi: 10.1007/s00464-020-07660-y. Epub 2020 May 29. PMID: 32472496.
14. **Sheng IY**, Barata P, Alameddine R, Garcia JA. Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer. *Drugs Context.* 2021 Mar 15;10:2020-10-2. doi: 10.7573/dic.2020-10-2. PMID: 33796138; PMCID: PMC7968923.
15. **Sheng IY**, Gupta S, Reddy CA, Angelini D, Funchain P, Sussman TA, Sleiman J, Ornstein MC, McCrae K, Khorana AA. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. *Target Oncol.* 2021 Nov;16(6):813-821. doi: 10.1007/s11523-021-00852-z. Epub 2021 Nov 6. PMID: 34741719.
16. **Sheng IY**, Wei W, Chen YW, Gilligan TD, Barata PC, Ornstein MC, Rini BI, Garcia JA. Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. *Clin Genitourin Cancer.* 2021 Feb;19(1):e12-e16. doi: 10.1016/j.clgc.2020.06.006. Epub 2020 Jul 11. PMID: 32800474.
17. **Sussman TA**, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. *J Immunother Cancer.* 2021 Jan;9(1):e001719. doi: 10.1136/jitc-2020-001719. PMID: 33436486; PMCID: PMC7805375.
18. **Wright MD**, Abraham MJ. Preclinical discovery and development of abemaciclib used to treat breast cancer. *Expert Opin Drug Discov.* 2021 May;16(5):485-496. doi: 10.1080/17460441.2021.1853097. Epub 2021 Jan 12. PMID: 33280445.
19. Cocco D, ElSherif A, **Wright MD**, Dempster MS, Kruse ML, Li H, Valente SA. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. *Ann Surg Oncol.* 2021 Oct;28(10):5723-5729. doi: 10.1245/s10434-021-10455-7. Epub 2021 Jul 29. PMID: 34324111.

Poster Presentations/Abstracts

1. **Dawsey S**, et. al. Prostate Cancer and COVID-19 Outcomes: from the Cleveland Clinic registry of COVID-19 and cancer patients. AACR Virtual Conference: COVID-19 and Cancer. Cleveland, OH. February 2021. (Poster)
2. **Dawsey S**, Pennell NA, **Lemmon C**, **Nizam A**, Wei W, Gilligan TD, Ornstein MC, Gupta S. Prostate cancer and COVID-19 outcomes: Results from the Cleveland Clinic registry of

COVID-19 and cancer patients. Poster presentation at AACR COVID-19 and Cancer Meeting; February 3, 2021; Virtual Meeting.

3. **Nizam A**, Sheng IY, Allman KD, Martin A, Gilligan TD, Gupta S, Ornstein MC. Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-related adverse events (irAEs). Poster presentation at ASCO Genitourinary Cancers Symposium; February 11, 2021; Virtual Meeting.
4. **Onger T**, et. al. Understanding Disparities in Cancer Pain Management. Case Comprehensive Cancer Center's 5th Annual Cancer Disparities Symposium Virtual Conference. March 2021 (Virtual Presenter)
5. **Sadaps M**, et. al. The impact of clinical decision making in a molecular tumor board at a tertiary care center. ASCO 2021 Annual Meeting. June 2021. Alexandria, VA. Virtual (Poster)
6. **Roof L**, et. al. Impact of socioeconomic disparities on diagnosis and overall survival in small cell lung cancer: A National Cancer Database analysis. ASCO 2021 Annual Meeting. Alexandria, VA. June 2021. Virtual (Poster)
7. **Wright M**, et. al. Assessing the impact of preoperative breast MRI on time to treatment for invasive lobular carcinoma. San Antonio Breast Conference. Antonio, TX. December 2021 (Poster)